MedTrace Logo

Study of IMC-11F8 in Participants With Colorectal Cancer

NCT00835185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).

Conditions

Interventions

BIOLOGICAL

IMC-11F8 (necitumumab)

IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1

DRUG

Oxaliplatin

Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1

DRUG

Folinic acid (FA)

FA 400 mg/m² IV infusion bolus injection

DRUG

5-FU

5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-01-31
Completion
2010-10-31

Countries

  • Belgium
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00835185 on ClinicalTrials.gov